Literature DB >> 23541670

Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.

Saul Jaime-Figueroa1, Javier De Vicente, Johannes Hermann, Alam Jahangir, Sue Jin, Andreas Kuglstatter, Stephen M Lynch, John Menke, Linghao Niu, Vaishali Patel, Ada Shao, Michael Soth, Minh Diem Vu, Calvin Yee.   

Abstract

We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold. The initial leads in this series, compounds 1a and 1h, showed promising potencies, but a lack of selectivity against other isoforms in the JAK family. Computational and crystallographic analysis suggested that the phenyl ether moiety possessed a favorable vector to achieve selectivity. Exploration of this vector resulted in the identification of 12b and 12d, as potent JAK3 inhibitors, demonstrating improved JAK family and kinase selectivity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541670     DOI: 10.1016/j.bmcl.2013.03.015

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.

Authors:  Maninder Kaur; Pankaj Kumar Singh; Manjinder Singh; Renu Bahadur; Om Silakari
Journal:  Mol Divers       Date:  2017-11-14       Impact factor: 2.943

Review 2.  Advances in kinase inhibition: treating rheumatic diseases and beyond.

Authors:  Massimo Gadina
Journal:  Curr Opin Rheumatol       Date:  2014-03       Impact factor: 5.006

Review 3.  The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.

Authors:  Bin Cai; Jian-ping Cai; Yu-long Luo; Cheng Chen; Sen Zhang
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

4.  Development of Selective Covalent Janus Kinase 3 Inhibitors.

Authors:  Li Tan; Koshi Akahane; Randall McNally; Kathleen M S E Reyskens; Scott B Ficarro; Suhu Liu; Grit S Herter-Sprie; Shohei Koyama; Michael J Pattison; Katherine Labella; Liv Johannessen; Esra A Akbay; Kwok-Kin Wong; David A Frank; Jarrod A Marto; Thomas A Look; J Simon C Arthur; Michael J Eck; Nathanael S Gray
Journal:  J Med Chem       Date:  2015-08-18       Impact factor: 7.446

5.  Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.

Authors:  Sathya Babu; Santhosh Kumar Nagarajan; Sruthy Sathish; Vir Singh Negi; Honglae Sohn; Thirumurthy Madhavan
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

6.  Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation.

Authors:  Jingyu Zhu; Qianqian Yu; Yanfei Cai; Yun Chen; Hui Liu; Wenqing Liang; Jian Jin
Journal:  Front Mol Biosci       Date:  2020-05-27

7.  Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.

Authors:  Alan Jiang; Qiufeng Liu; Ruifeng Wang; Peng Wei; Yang Dai; Xin Wang; Yechun Xu; Yuchi Ma; Jing Ai; Jingkang Shen; Jian Ding; Bing Xiong
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

8.  Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma.

Authors:  Xiangkun Wang; Xiwen Liao; Tingdong Yu; Yizhen Gong; Linbo Zhang; Jianlu Huang; Chengkun Yang; Chuangye Han; Long Yu; Guangzhi Zhu; Wei Qin; Zhengqian Liu; Xin Zhou; Junqi Liu; Quanfa Han; Tao Peng
Journal:  Int J Oncol       Date:  2019-08-27       Impact factor: 5.650

9.  Pharmacophore and Virtual Screening of JAK3 inhibitors.

Authors:  Murugesan Rajeswari; Natchimuthu Santhi; Vembu Bhuvaneswari
Journal:  Bioinformation       Date:  2014-03-19

Review 10.  JAK/STAT pathway and molecular mechanism in bone remodeling.

Authors:  Eliana Rita Sanpaolo; Cinzia Rotondo; Daniela Cici; Ada Corrado; Francesco Paolo Cantatore
Journal:  Mol Biol Rep       Date:  2020-10-24       Impact factor: 2.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.